Successful treatment of cerebral vasculitis in an HIV-positive patient with anti-CD25 treatment [10]

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1677-1678

  Nieuwhof, C M G ^a   Damoiseaux, J ^a   Tervaert, J W Cohen ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CLARITHROMYCIN; CYCLOSPORIN A; DACLIZUMAB; EFAVIRENZ; LAMIVUDINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; PREDNISONE; ZIDOVUDINE;

ADULT; BRAIN BIOPSY; BRAIN VASCULITIS; CASE REPORT; DYSARTHRIA; DYSPHAGIA; FACE DEFORMITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LABORATORY TEST; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PRIORITY JOURNAL; SEROLOGY; THRUSH;

ADULT; AIDS ARTERITIS, CENTRAL NERVOUS SYSTEM; ANTIBODIES, MONOCLONAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE;

EID: 33751273732     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.044867     Document Type: Letter

References (10)

1. Van der Ven A, van Oostenbrugge R, Kubat B, Cohen Tervaert JW. Cerebral vasculitis after initiation antiretroviral therapy. AIDS 2002; 16:2362-4.
2. Lie JT. Primary (granulomatous) angiitis of the central nervous system: a clinicopathological analysis of 15 new cases and review of the literature. Hum Pathol 1992;23:164-171.
3. Nussenblatt R, Thompson D, Li Z, Peterson J, Robinson R, Shames R, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21:283-93.
4. Przepiorka D, Kernan N, Ippoliti C, Papadopoulos E, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-89.
5. Renkl A, Mockenhaupt M, Technau K, Herouy Y, Norgauer J. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD 25 antibody. Br J Dermatol 2004;150:1220-22.
6. Tomaske M, Amon O, Bosk A, Handgretinger R, Marion Schneider E, Niethammer D. Anti-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 2002;38:141-2.
7. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, et al. A Pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76.
8. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004;101:8705-8.
9. Hardy G, Imami N, Sullivan A, Pires A, Burton C, Nelson M, et al. Reconstitution of CD4+ T cells responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003;134:98-106.
10. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunological tolerance is maintained by activated T cells expressing IL-2 receptor a chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151.